Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cybin Inc. - Common Stock
(NQ:
HELP
)
4.640
-0.490 (-9.55%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,587,876
Open
5.200
Bid (Size)
4.750 (100)
Ask (Size)
4.850 (200)
Prev. Close
5.130
Today's Range
4.640 - 5.350
52wk Range
4.640 - 8.970
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Jill Conwell as Chief People Officer
March 12, 2026
Via
Investor Brand Network
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer
March 12, 2026
From
Helus Pharma
Via
GlobeNewswire
Performance
YTD
-40.0%
-40.0%
1 Month
-28.5%
-28.5%
3 Month
-40.0%
-40.0%
6 Month
-40.0%
-40.0%
1 Year
-40.0%
-40.0%
More News
Read More
HELP Stock Crashes On Anxiety Trial Results, But Here’s Why Jefferies Sees Up To 200% Upside
↗
March 05, 2026
Via
Stocktwits
Dow Futures Hold Ground After 800-Point Selloff As Oil Surge Hits Wall Street: Why MRVL, USO, COST, HELP Are Trending After-Hours
↗
March 05, 2026
Via
Stocktwits
Topics
ETFs
Stocks
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Positive Phase 2 Results for HLP004 in Generalized Anxiety Disorder
March 05, 2026
Via
Investor Brand Network
Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion
March 05, 2026
Via
FinancialNewsMedia
HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism
↗
March 05, 2026
Via
Stocktwits
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
March 05, 2026
From
Helus Pharma
Via
GlobeNewswire
TinyGemsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Dr. Freda Lewis-Hall to Board and Scientific Advisory Committee Chair
February 24, 2026
Via
Investor Brand Network
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
February 24, 2026
Via
FinancialNewsMedia
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
February 24, 2026
Via
FinancialNewsMedia
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
February 24, 2026
From
Helus Pharma
Via
GlobeNewswire
Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise
↗
February 20, 2026
Via
MarketBeat
HELP Stock Rallies After Experimental Depression Drug Reduces Symptoms In Study: Retail Thinks Its ‘Time To Buy More’
↗
February 17, 2026
Via
Stocktwits
PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Positive Phase 2a SPL026 Data Published in Nature Medicine
February 17, 2026
Via
Investor Brand Network
Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
February 17, 2026
From
Helus Pharma
Via
GlobeNewswire
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Q3 2025 Results, Advances Phase 3 and Phase 2 Programs
February 13, 2026
Via
Investor Brand Network
Topics
Intellectual Property
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
February 13, 2026
From
Helus Pharma
Via
GlobeNewswire
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Michael Cola as Chief Executive Officer
February 10, 2026
Via
Investor Brand Network
Topics
Intellectual Property
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
February 10, 2026
Via
FinancialNewsMedia
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
February 10, 2026
Via
FinancialNewsMedia
Topics
Intellectual Property
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
February 10, 2026
From
Helus Pharma
Via
GlobeNewswire
Frequently Asked Questions
Is Cybin Inc. - Common Stock publicly traded?
Yes, Cybin Inc. - Common Stock is publicly traded.
What exchange does Cybin Inc. - Common Stock trade on?
Cybin Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cybin Inc. - Common Stock?
The ticker symbol for Cybin Inc. - Common Stock is HELP on the Nasdaq Stock Market
What is the current price of Cybin Inc. - Common Stock?
The current price of Cybin Inc. - Common Stock is 4.640
When was Cybin Inc. - Common Stock last traded?
The last trade of Cybin Inc. - Common Stock was at 03/13/26 04:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.